Rimonabant
From Library of Congress Subject Headings
Rimonabant
URI(s)
- http://id.loc.gov/authorities/subjects/sh2007005971
- info:lc/authorities/sh2007005971
- http://id.loc.gov/authorities/sh2007005971#concept
Instance Of
Scheme Membership(s)
Collection Membership(s)
Variants
- Acomplia (Trademark)
- Rimonabant hydrochloride
- Rimoslim
- Riobant
- Slimona
- SR141716
- Zimulti (Trademark)
Broader Terms
Sources
- found: Work cat.: Pi-Sunyer, F.X. Biography of Rimonabant, 2007.
- found: Journal of the American College of Cardiology, vol. 47 (2006): pp. 1919-1926 (Rimonabant: a cannabinoid receptor type 1 blocker for management of multi cardiometabolic risk factors)
- found: Drugs today, Aug. 2005: pp.499-508 (Rimonabant hydrochloride, the first drug in a new class of selective cannabinoid type 1 (CB1) receptor antagonists, is showing promise in clinical trials for the treatment of obesity and related metabolic risk factors, in addition to tobacco dependence)
- found: Wikipedia, 31 July 2007: Rimonabant (Rimonabant (also known as SR141716, Acomplia, Riobant, Slimona, Rimoslim, and Zimulti) is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Rimonabant is currently being sold in the United Kingdom by Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name Acomplia (which is the name used in 18 countries, as of 2007). Riobant, Slimona and Rimoslim are generic forms available in India. If approved in the United States, it is intended to be marketed under the name Zimulti)
Change Notes
- 2007-07-31: new
Alternate Formats
Suggest terminology
The LC Authorities and Vocabularies service welcomes any suggestions you might have about terminology used for a given heading or concept.
Would you like to suggest a change to this heading?
Please provide your name, email, and your suggestion so that we can begin assessing any terminology changes.
Alternatively, you can contact us directly at idfeedback@loc.gov.
Fields denoted with an asterisk (*) are required.
